Medienmitteilungen

26 Apr 2024
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
23 Apr 2024
Idorsia publishes an invitation to a bondholder meeting
17 Apr 2024
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
11 Apr 2024
Idorsia takes steps to address short-term liquidity needs
22 Mar 2024
Idorsia thanks Guy Braunstein for his years of service as he retires
20 Mar 2024
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
18 Mar 2024
Idorsia and Viatris successfully close the transaction for the global research and development collaboration
28 Feb 2024
Idorsia and Viatris enter into a significant global research and development collaboration
10 Jan 2024
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
03 Nov 2023
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
24 Oct 2023
Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt – Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert
23 Oct 2023
Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023
06 Sep 2023
Idorsia reacquires the world-wide rights to aprocitentan
25 Jul 2023
Idorsia gibt Finanzergebnisse für das erste Halbjahr 2023 bekannt – Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert
21 Jul 2023
Idorsia kündigt eine Kostensenkungsinitiative an, die bis Ende 2023 umgesetzt werden soll
20 Jul 2023
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million
10 Jul 2023
Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS
26 Jun 2023
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023
23 Jun 2023
New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 202
20 Jun 2023
Idorsia has secured bridge financing in the amount of CHF 75 million

Ad-hoc-Mitteilungen gemäss Art. 53 KR

Ad-hoc-Mitteilungen gemäss Art. 53 KR sind ab dem Jahr 2021 klassifiziert worden. Ein vollständiges Archiv der Pressemitteilungen finden Sie unter der Registerkarte "All".